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Abstract
Direct measurement of insulin is critical for basic and clinical studies of insulin secretion.
However, current methods are expensive and time-consuming. We developed an insulin
assay based on homogenous time-resolved fluorescence that is significantly more rapid
and cost-effective than current commonly used approaches. This assay was applied effec-
tively to an insulin secreting cell line, INS-1E cells, as well as pancreatic islets, allowing us
to validate the assay by elucidating mechanisms by which dopamine regulates insulin
release. We found that dopamine functioned as a significant negative modulator of glucose-
stimulated insulin secretion. Further, we showed that bromocriptine, a known dopamine D2/
D3 receptor agonist and newly approved drug used for treatment of type II diabetes mellitus,
also decreased glucose-stimulated insulin secretion in islets to levels comparable to those
caused by dopamine treatment.
Introduction
Insulin is an anabolic hormone that regulates metabolism and energy homeostasis. The release
of insulin by pancreatic beta cells in response to increases in extracellular glucose promotes glu-
cose uptake in insulin-sensitive tissues [1]. Disruption of the regulation of insulin secretion
leads to profound global metabolic effects that can result in diabetes mellitus and tissue damage
[2]. Many aspects of insulin release, including the mechanisms regulating glucose-stimulated
insulin secretion (GSIS), require further study. For example, emerging evidence suggests that
peripheral dopamine (DA) is an important modulator of GSIS [3]. Moreover, several antipsy-
chotic drugs, which target DA D2-like receptors including D2 (D2R) and D3 (D3R) receptors,
significantly dysregulate insulin secretion [3,4]. Thus, a rapid, cost-effective and scalable assay
for quantitating insulin levels would facilitate further studies of GSIS and drug-induced
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metabolic syndromes and, more generally, would be useful in a variety of clinical, academic
and industrial settings.
To date, the predominant methods used to measure insulin are radioimmunoassay (RIA)
and enzyme-linked immunosorbent assay (ELISA) [5–7]. RIA was the first widely used assay
for insulin detection [5]. However, this approach is limited by potential safety concerns due to
the use of radiolabeled antigen, the instability of the reagents and the need for extended incuba-
tion and washing steps [8]. The development of an ELISA-based assay has allowed for the
detection of insulin without the need for radioactive reagents. Although ELISA is currently the
gold standard assay for measuring insulin, it is expensive (>$2/sample), and, like RIA, is also
labor intensive and thus relatively low-throughput [9–11]. The recently developed homoge-
nous insulin assay, AlphaLISA, relies on oxygen channeling chemistry to generate singlet oxy-
gen which initiates a chemiluminescent reaction following insulin binding [11]. This approach,
which requires fewer overall steps compared to ELISA, has facilitated higher-throughput
screening. Nevertheless, this assay displays limited signal stability, as it is highly sensitive to
ambient light exposure, singlet oxygen sequestration and photobleaching [12]. Thus, a real
need still exists for a reliable, rapid and affordable insulin assay amenable to high-throughput
studies. To address this, here we used homogenous time-resolved fluorescence (HTRF) [13,14]
to design a cell-based assay for rapid detection and measurement of insulin, resulting in a sim-
ple yet robust, cost-effective ($0.20/sample) and sensitive insulin detection assay capable of
being read by numerous microplate readers. We then used this assay to measure insulin release
from two complementary experimental systems: INS-1E cells, a widely used and well-charac-
terized insulin-secreting rat beta cell-derived cell line [15] as well as from mouse pancreatic
islets. As a proof-of-principle, we further validated our HTRF insulin assay by examining the
roles of DA and D2R/D3R signaling in mediating GSIS, which we and colleagues have recently
shown to act as components of an autocrine/paracrine negative feedback mechanism [3,16,17].
Lastly, we expanded on these findings by examining effects of bromocriptine, a known dopa-
mine D2/D3 receptor agonist [18,19], on GSIS in mouse islets using our HTRF-based assay.
Though bromocriptine was recently newly approved for treatment of type II diabetes mellitus
[18,20–23], to date, the precise molecular mechanisms responsible for its efficacy remain
poorly understood. Here, consistent with earlier data suggesting that the drug can modify GSIS
[24], we show that bromocriptine acts directly on islets as a negative mediator of GSIS, provid-
ing a putative molecular mechanism for its actions in the pancreas.
Materials and Methods
Cell Culture
Rat beta cell-derived INS-1E cells (gift of P. Maechler, Université de Genève; [15]) were main-
tained in a humidified 37°C incubator with 5% CO2. The cells were cultured with RPMI 1640
medium (Life Technologies, Norwalk, CT) supplemented with 5% (v/v) heat inactivated fetal
bovine serum, 2 mM L-glutamine, 10 mMHEPES, 1 mM sodium pyruvate, 100 units/mL peni-
cillin, 100 μg/mL streptomycin, and 50 μM 2-mercaptoethanol.
Mice and Pancreatic Islet Preparation
All animals were housed and handled in accordance with all appropriate NIH guidelines
through the Columbia University Institute of Comparative Medicine. The institutional review
board and ethics committee of Columbia University Medical Center approved the study. We
abided by all appropriate animal care guidelines including ARRIVE guidelines for reporting
animal research (S1 File) [25,26]. All efforts were made to ameliorate animal suffering. Animal
sacrifice was humanely performed by cervical dislocation for adult mice.
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Wildtype C57Bl6/J mice were purchased from rotavirus-free colonies of Jackson Laboratory
(Bar Harbor, ME). For mouse pancreatic islet preparations, wildtype 8–10 week old male and
female C57Bl6/J mice weighing ~25–30 g were used. Mice were housed in cages with a 12:12
light:dark cycle and had access to food and water ad lib at all times. Pancreatic islets were iso-
lated via collagenase digestion as described previously [27]. Each experiment used 3 mice to
obtain sufficient numbers of islets for that respective day’s conditions with every condition per-
formed either in triplicate or quadruplicate (21 mice used in total). Islets were seeded at the fol-
lowing densities: 10 islets per well in 24-well plates or single islets in each well of a 96-well
plate. We then standardized the islets per well based on islet size and morphology using a dis-
secting microscope according to methods established in earlier studies [28–31]. Islets of rela-
tively uniform size and shape were evenly distributed throughout the wells, as indicated by
Hopcroft et al. (1985) and Colella et al. (1985) [29,30]. The islets were then cultured free-float-
ing overnight in RPMI 1640 media supplemented with 10% fetal bovine serum prior to experi-
mental use the following day.
Compounds
The compounds used in the present study were as follows and purchased from Sigma-Aldrich
(St. Louis, MO) unless indicated otherwise: D-glucose, dopamine (3-hydroxytyramine HCl),
HEPES, sodium pyruvate, penicillin, streptomycin, 2-mercaptoethanol. Human, bovine and
porcine insulin were also obtained from Sigma-Aldrich. Rodent (rat/mouse-reactive) insulin
was obtained from ALPCO (Salem, NH). Human proinsulin was obtained from R&D Systems
(Minneapolis, MN) and human C-peptide was purchased from AnaSpec, EGT (Fremont, CA).
Bromocriptine mesylate was purchased from Tocris (Bristol, United Kingdom).
HTRF insulin assay
The HTRF insulin detection assays were performed in either half-area, 96-well or 384-well
plates (Greiner Bio-One, Monroe, NC) by adding both anti-insulin antibody coupled to Euro-
pium cryptate and a second anti-insulin antibody coupled to XL665 (Cisbio Bioassays, Bedford,
MA) to the respective samples in a 1:1 ratio (total antibody volume:sample volume). Antibody
incubation was conducted for 2 h at room temperature (25°C) with pH 7 buffer unless other-
wise specified. The resulting fluorescence emissions were read by a multi-mode microplate
reader (PHERAstar FS, BMG Labtech, Ortenberg, Germany) which utilized a 337 nm nitrogen
laser for fluorophore excitation, a 620 nm filter for Europium cryptate fluorescence reading,
and a 665 nm filter for the XL665 fluorescence detection. Data were reported as the ratio of
fluorescence measured at 665nm (XL665) and 620 nm (Europium cryptate) with the signal at
620 nm functioning as an internal standard following a 40 μs time delay. Insulin standards
were set up for each plate by diluting known insulin concentrations (0.312–15 ng/mL). HTRF
measurements of these standards were fit to a standard curve fit with a second order polyno-
mial (quadratic) regression line (y = B0+B1x+B2x
2) via GraphPad Prism software (version 6.0,
GraphPad Software, Inc., La Jolla, CA) allowing for interpolation of raw HTRF values from the
experimental samples to known insulin concentration values.
The ability of the assay’s antibodies to recognize insulin across species involved measure-
ment of HTRF signals of increasing concentrations of human, bovine, porcine and rodent insu-
lin. The respective HTRF signals were plotted as Log [insulin concentration] versus the ΔF%
where ΔF% was defined as [(mean HTRF ratio of a sample)–(mean HTRF ratio of the zero
standard)/(mean HTRF ratio of the zero standard)]; the zero standard was defined as a sample
with assay buffer only (0 ng/mL insulin). This permitted comparison of HTRF signals from the
respective species’ insulin across a range of insulin concentrations (0.01–10 nM). Additionally,
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we measured the ability of the assay’s antibodies to recognize either human proinsulin or
human insulin C-peptide. In the case of the proinsulin recognition, we measured the respective
HTRF signals across a range of proinsulin concentrations (12.3–195 pM) and compared with
equivalent concentrations of human insulin. We also measured HTRF signals for C-peptide
across a broad concentration range (2–20,000 pM).
For cell-based glucose stimulation experiments, we measured the amount of insulin secreted
in collected supernatant as well as residual cellular insulin content from whole cell lysate. INS-
1E cells were seeded into individual wells of a 24-well plate at an initial seeding density of 5.0 x
105 cells/well unless described otherwise. RPMI 1640 media was exchanged 24 h after cell seed-
ing and experiments were conducted the following day. On the day of the insulin secretion
assay, the INS-1E cells underwent a glucose starvation step (1 h, 37°C) by exchange of RPMI
1640 medium (which contains 11 mM glucose) with glucose-free (0 mM glucose) KRB buffer
(132.2 mM NaCl, 3.6mM KCl, 5mMNaHCO3, 0.5 mMNaH2PO4, 0.5 mMMgCl2, 1.5 mM
CaCl2, and 0.001 g/mL bovine serum albumin), as described previously [15]. The cells were
then stimulated with glucose (20 mM glucose unless specified otherwise) in KRB buffer for 90
min, 37°C; 20 μL of supernatant from each sample was subsequently collected for the insulin
assay. Similarly, for mouse islets secretion studies, islets seeded in either 24-well or 96-well
plates (for single islet secretion experiments) were glucose-starved in KRB buffer containing
2.8 mM glucose (1 h, 37°C) as described in earlier studies [3,32]. Following starvation, the islets
were stimulated with 20 mM glucose in KRB in the presence or absence of additional drugs. At
the conclusion of stimulation, we collected 10 μL of supernatant from each sample to measure
secreted insulin content. For the INS-1E-cell-based assay (conducted in the 96-well plates),
10 μL of each antibody (20 μL total antibody volume) was added to 20 μL of cell supernatant.
Likewise, in the islet-based assays (conducted in 384-well plates), 5 μL of each antibody was
added to 10 μL of islet supernatant. Following 30–90 min of glucose stimulation of the INS-1E
cells, HTRF signal from the supernatant was ultimately reported either as insulin concentration
values (in ng/mL) or as the percent of maximal stimulated insulin secretion which was calcu-
lated as the ratio of [insulin concentration for a respective sample]/[maximal insulin concen-
tration within an experiment]. Further, GSIS was defined as the difference between maximal
stimulated and basal (unstimulated) insulin release with effects of drugs on GSIS determined
relative to this difference; the unstimulated condition was defined as 0 mM glucose for experi-
ments using INS-1E cells and 2.8 mM glucose for pancreatic islet studies of GSIS as based on
earlier studies [3,15,32].
To measure intracellular insulin content in INS-1E cells, we first washed adherent INS-1E
cells with KRB buffer to remove any secreted insulin from the supernatant. We next added a
Triton X-100-based cell lysis solution consisting of 25% (v/v) 4x concentrated cell lysis buffer
(4X Cell phospho/total protein lysis buffer #1 containing 25% Triton X-100, pH 7; Cisbio Bio-
assays, Bedford, MA) and 75% KRB (v/v) to the cells. The cells were then shaken at 25°C for 30
min. Insulin content of the prepared lysates was subsequently determined via HTRF. Similarly,
to assay intracellular insulin content in pancreatic islets, islets from wildtype C57Bl6/J mice
were isolated (as described earlier) and cultured overnight in RPMI 1640 supplemented with
10% newborn calf serum overnight (5% CO2, 37°C). Islets were then lysed after treatment with
25% (v/v) 4x Cell phospho/total protein lysis buffer #1 and 75% KRB (v/v) at 25°C for 30 min.
The resulting islet lysate was used to determine intra-islet insulin concentration by HTRF.
Given that insulin concentrations in cell and islet-derived supernatants and lysates were
typically greater than the concentrations used to generate the standard curves, to determine
accurate insulin concentrations, we needed to bring our samples’ insulin concentrations into
the standard curve’s linear range by appropriately diluting our samples. Following interpola-
tion of the diluted insulin concentrations, we obtained the insulin concentrations of the
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original, undiluted samples by multiplying the diluted insulin concentrations by the respective
dilution factors for each treatment condition.
ELISA insulin assay
INS-1E cells were seeded at an initial density of 5.0x105 cells/well in each well of a 24-well plate
as described in the preceding section. Following 90 min of glucose stimulation, in parallel to
HTRF measurements, 20 μL of supernatant was transferred to a 96-well plate and insulin levels
were measured using the insulin rodent ELISA chemiluminescence kit [American Laboratory
Products Company (ALPCO), Salem, NH] as described previously [33,34]. Briefly, the ELISA
assay conducted was a sandwich type immunoassay using a 96-well microplate coated with an
anti-insulin monoclonal antibody. Samples and insulin standard controls were added to the
plate, incubated for 2 h at room temperature with shaking and followed by 6 washes. Chemilu-
minescent signal was subsequently read on a PHERAstar FS microplate reader using a 1 s inte-
gration time.
Cell viability assay
Effects of glucose stimulation on cell viability were determined using the VivaFix Cell Viability
Assay (Bio-Rad Laboratories, Inc., Hercules, CA) that relies on fluorescent VivaFix dye that is
concentrated into dead cells while excluded from live ones. INS-1E cells were seeded at an ini-
tial density of 5.0x105 cells/well in a 24-well plate. RPMI 1640 media was exchanged 24 h after
cell seeding and experiments were conducted the following day. We stimulated cells with 20
mM glucose (90 min, 37°C) while unstimulated control cells remained in KRB buffer (0 mM
glucose, 90 min, 37°C) according to conditions identical to our HTRF insulin assay. Cells from
each respective condition were collected with Enzyme Free Cell Dissociation Solution (EMD
Millipore, Billerica, MA) and resuspended in Dulbecco’s PBS buffer (DPBS; Thermo Fisher Sci-
entific Inc., Waltham, MA). Cells were incubated with VivaFix dye (30 min, 37°C), washed
twice with DPBS, and placed into a flow cytometer (BD Accuri C6 Flow Cytometer; BD Biosci-
ences, Franklin Lakes, NJ). Labeled and unlabeled cells in both stimulated versus unstimulated
conditions were then counted by plotting the differences in fluorescence intensity measured at
675 ± 12 nm using BD CSampler Software (BD Biosciences).
Z´-factor analysis
Z0-factor values for the HTRF insulin assay were calculated from multiple samples in a single
experiment as described in Zhang (1999) [35]. We determined these values by comparing
HTRF readings from different insulin concentrations (1 ng/mL versus 10 ng/mL or 2.5 ng/mL
versus 10 ng/mL). Briefly, we obtained HTRF ratios from multiple replicates of each of these
insulin concentrations (1, 2.5 and 10 ng/mL) that were read on a given day and used these val-
ues to calculate the mean HTRF signal and standard deviations (SD) for these respective con-
centrations. The Z´-factor was then defined as 1-[3(SDhigher concentration−SDlower concentration)/
(Meanhigher concentration−SDlower concentration)] or the ratio defining the separation of respective
HTRF signals between any two insulin concentrations based on bounds defined by 3 SD. We
also established the Z0-factor for our cell-based GSIS assay by comparing multiple replicates of
HTRF readings from supernatant samples collected from glucose-stimulated (20 mM glucose)
versus unstimulated (KRB alone with 0 mM glucose) INS-1E cells on a single experimental
day. Mean secreted insulin values were obtained from unstimulated background (KRB alone
condition) and stimulated (20 mM glucose) conditions.
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Statistical Analyses
SPSS (version 18.0, IBM, Armonk, NY) was used for all statistical analyses unless stated other-
wise. Fitting insulin concentrations derived from HTRF and ELISA assays to a linear regression
curve yielded both the coefficient of determination (R2) and slope indicating extent of agree-
ment for the respective insulin values derived from the respective methods. The R2 value for
insulin standard curves was derived via interpolation of ratiometric fluorescence readings to a
second order quadratic polynomial curve. Sigmoidal dose response curves were fit via non-lin-
ear regression of Log (ligand) versus either HTRF signal or normalized % maximal insulin
secretion values. All curve fittings were plotted using GraphPad Prism (version 6.0). The
respective signal to noise ratios (SNR) for the HTRF and ELISA signals were calculated as a
ratio of the average fluorescence intensity to the standard deviation of background fluores-
cence. The coefficient of variance (CV) of HTRF measurements for estimating reagent stability
was calculated as a ratio of the standard deviation (σ) to the mean (μ), or σ/μ, using the HTRF
ratios obtained from measurement of the 10 ng/mL human insulin standard across 19 separate
experimental days over a total period of 4 months.
The respective limits of detection (LOD) for the HTRF and ELISA-based insulin assays
were determined by first calculating the Limit of Blank (LOB), where LOB is the highest appar-
ent analyte concentration expected to be measured in blank sample (0 ng/mL standard) repli-
cates, or LOB = meanblank + 1.645(SDblank) [36]; we used 48 blank replicates consisting of KRB
buffer for the LOB calculation. We then calculated the LOD using either the HTRF ratios or
ECL signal associated with the LOB and the standard deviation associated with replicates of the
lowest concentration human insulin standard (0.156 ng/mL) used in our assays, based on the
formula: LOD = LOB + 3(SDlow concentration insulin sample) where the value was expressed as an
HTRF ratio or ECL signal [36,37]. These respective values were then fit to an insulin standard
curve to derive the final LOD insulin concentration (expressed in ng/mL). Like the LOD, the
limit of quantitation (LOQ) for both HTRF and ELISA insulin detection assays was determined
using the HTRF ratios or ECL signals associated with the LOB and the standard deviation asso-
ciated with replicates of the lowest concentration human insulin standard (0.156 ng/mL),
based on the formula: LOD = LOB + 10(SDlow concentration insulin sample) [37]. The resulting val-
ues were fit to an insulin standard curve to derive the final LOD concentration as expressed in
ng/mL. For both LOD and LOQ calculations, GraphPad 6.0 was used to determine respective
standard deviation values as well the fits for the insulin standard curves (second order polyno-
mial quadratic regression).
For analysis of drug effects on HTRF insulin assay readings from cells and islets, respective
treatment conditions were compared to control conditions via univariate ANOVA (α = 0.05)
followed by Bonferroni post-hoc tests to compare between-group differences using SPSS. For
determination of the proportion of secreted insulin to total cellular stores and for comparisons
in single islet secretion assays, we used a 2-tailed t-test to determine significance. EC50 and IC50
values were computed via a nonlinear, least-squares regression analysis using GraphPad Prism.
Results and Discussion
The HTRF insulin assay we developed relies on a combination of fluorescence energy transfer
(FRET) and time resolved (TR) technologies to quantify insulin levels [13,14,38]. This assay
uses insulin-binding antibodies labeled with either a long-emitting energy donor, Europium
cryptate (EuK), or the near-infrared energy acceptor, XL665, the emission spectrum of which
is minimally contaminated by fluorescence from other compounds in solution [14] (Fig 1A).
When both antibodies recognize their respective insulin epitopes, efficient and long-lived
FRET occurs between the EuK donor and the XL665 acceptor (Fig 1B). We measured emission
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ratiometrically [665 nm (acceptor)/620 nm (donor)] to reduce well to well variation [14]. Spe-
cific detection of the stable EuK-XL665 FRET signal was significantly enhanced by the addition
of a time delay that filtered out interference from transient assay buffer and protein autofluor-
escence (Fig 1C). We used this detection method to measure insulin released from cells or islets
treated in the following manner: (1) insulin-secreting cells or islets were stimulated with secre-
tagogue (i.e., glucose), followed immediately by (2) the transfer of the insulin-containing super-
natant (or cell lysate) to a separate plate where the donor and acceptor-coupled insulin
antibodies were added, incubated and measured directly without the need for additional wash
steps (Fig 1D).
We first examined effects of pH, incubation time and temperature on the measurement of
insulin standards, given that antibody-based detection assays in general are sensitive to these
parameters [39]. Incubation at pH 7 produced higher HTRF values compared to pH 5 or 9
(p<0.001; Fig 2A), although robust signals were still detected at the pH extremes. We next
assessed the change in signal strength over time by measuring HTRF values following 2, 12 and
Fig 1. Principles of the HTRF insulin assay. (A) The HTRF assay is based on detection of a measurable FRET signal upon binding of anti-insulin
antibodies coupled to the energy donor, Europium cryptate (EuK), and those with the near-infrared energy acceptor, XL665. (B) In the absence of insulin
binding, there is no detectable FRET fluorescence and only donor emission is measured (λem = 620 nm) due to physical separation between the donor and
acceptor fluorophores (>10 nm). When both antibodies concurrently bind insulin, the resulting physical proximity between the donor/acceptor pair results in
FRET and an acceptor emission (λem = 665 nm; red emission curve). FRET is measured ratiometrically [665 nm (acceptor)/620 nm (donor)]. (C)Given the
long-lived nature of the donor fluorescence, a 40 μs time delay prior to fluorescence measurement significantly enhances signal specificity by eliminating
shorter-lived autofluorescence. (D) Applying these principles, we developed a homogenous insulin assay whereby levels of secreted insulin in the
supernatant or within the cell are transferred to a plate where the donor and acceptor-coupled insulin antibodies are directly added, incubated and read by a
plate reader.
doi:10.1371/journal.pone.0148684.g001
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48 h incubations. Overall, there was a progressive increase in signal strength over time (Fig
2B). Importantly, the 2 h antibody incubation produced a robust signal and a standard curve
with a well-defined linear range, suggesting a reasonable balance between signal intensity to
detect changes in insulin concentration and total assay time (Fig 2B). Our detection of a strong
HTRF signal for at least 48 h also suggests that the assay reagents were stable throughout this
period. We further examined reagent stability over a 4 month period, finding a highly reliable
HTRF signal with a coefficient of variation (CV) that was only 4.3% (n = 19 trials).
We also observed a temperature-dependent difference in HTRF signal whereby antibody
incubation at room temperature (25°C) produced a greater HTRF signal compared to incuba-
tion at 37°C during a 2 h incubation (p<0.001; Fig 2C). Additionally, we examined the species
cross-reactivity of the insulin antibodies (Fig 2D). The antibodies recognized rodent, bovine,
porcine and human insulin with no significant differences in HTRF signal (p>0.05) across a
Fig 2. Validation of HTRF insulin assay conditions. (A) pH significantly affected the ratiometric HTRF signal across a range of human insulin
concentrations [F(2, 40) = 21.35, p<0.001]. Antibody incubation at pH 7 yielded the greatest HTRF signal compared to other pHs (p<0.001). (B) 2 h antibody
incubation was sufficient to produce a robust HTRF signal, with longer antibody incubation times (12 and 48 h) further increasing HTRF signal. (C) There was
a temperature-dependent difference in HTRF values when antibodies were incubated for 2 h at room temperature (RT, 25°C) versus 37°C [F(1,29) = 16.57,
p<0.001] with higher signal observed at RT. (D) There was no significant difference in HTRF signal between human, rodent, porcine and bovine insulin
across a range of concentrations (0.01–10 nM; p>0.05). Panels A-C: Data are represented as the mean emitted HTRF ratio ± SEM. Panel D:Data are
represented as %ΔF of the HTRF signal for the respective species. For all panels, the data are from experiments performed in triplicate in 384-well plates.
doi:10.1371/journal.pone.0148684.g002
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range of insulin concentrations (0.01–10 nM). Furthermore, we examined whether the insulin
antibodies cross-reacted with either C-peptide or proinsulin. The antibodies did not recognize
C-peptide concentrations as high as 20 μM and demonstrated 10% recognition of proinsulin
compared to mature insulin across a low concentration range (up to100 pM) (S1 Fig). Despite
a small degree of proinsulin recognition at high concentrations in vitro, it is likely not relevant
for applications that are based on measurement of secreted insulin of which>97% is in the
mature form [40]. Additionally, intracellular insulin stores are comprised almost exclusively of
crystallized mature insulin with proinsulin constituting only ~10% of the total cellular insulin
[40].
Using the parameters identified above (pH 7, 2 h incubation, 25°C), we measured insulin
release from rat pancreatic beta cell-derived INS-1E cells, one of the most widely used and
well-characterized cell lines currently used to study GSIS [15]. In contrast to other beta cell-
derived cell lines, an important advantage of using INS-1E cells is their robust, reproducible
insulin secretory response following glucose stimulation [15]. Because secretion of insulin is a
dynamic process, we profiled the kinetics of release following glucose stimulation. Insulin
release was significantly higher following 20 mM glucose treatment compared to unstimulated
cells (KRB alone) over a 90 min time course [F(3,112) = 77.64, p<0.001; Fig 3A]. Since the glu-
cose concentration of the culture media is 11 mM [15], we addressed the potential confound of
the media’s effects on GSIS through institution of a 1 h glucose starvation step prior to our
experimental manipulations (see Materials and Methods). This initial glucose starvation step
has been used widely since it improves the sensitivity of insulin-secreting cells to subsequent
GSIS, thus providing a greater dynamic range of secretory [41,42]. A glucose starvation step
also has the additional benefit of synchronizing the cells across treatments, which ultimately
reduces cell-to-cell variability in rates of GSIS [43]. To further optimize this assay, we examined
the effect of cell density on GSIS. As expected, the level of insulin secretion induced by 20 mM
glucose increased linearly with the number of INS-1E cells seeded per well (R2 = 0.99), with the
least inter-experimental variability at the two highest seeding cell densities tested (Fig 3B).
Consequently, we used an initial seeding density of 5.0x105 cells/well for all subsequent experi-
ments. On the day of the assay (2 days post-seeding), the final cell density was 9.5 ± 0.3x105
cells/well.
We next examined the concentration-dependence of GSIS in INS-1E cells (Fig 3C) and
found the EC50 of glucose to be 5.91 ± 0.02 mM (R
2 = 0.85). Moreover, because previous work
has shown that islets release only a fraction of their total cellular insulin stores during GSIS
[44], we determined the percentage of the maximal glucose-stimulated insulin release (at 20
mM glucose stimulation) relative to the total intracellular insulin content and found it to be
2.22 ± 0.37% compared to 0.56 ± 0.06% in the unstimulated state (0 mM glucose) (p<0.001; S2
Fig).
Based on the above data, we chose a concentration of 20 mM glucose (90 min, 37°C) to elicit
GSIS in our subsequent experiments. We assessed for potential glucotoxicity with a fluorescent
dye-based cell viability assay in INS-1E cells (see Materials and Methods) and found no signifi-
cant difference in the number of dead cells in the 20 mM glucose-stimulated group compared
to the unstimulated control (p>0.05; data not shown). These data therefore strongly suggested
that our glucose stimulation conditions were not cytotoxic.
We next compared the HTRF insulin assay directly with an ELISA-based insulin assay by
measuring secreted insulin from 20 mM glucose-stimulated cells from the same samples and
found close correlation between the two assays (slope = 1.15 ± 0.16, R2 = 0.84; Fig 4). We also
calculated the lower limits of detection (LOD) and quantitation (LOQ) for the HTRF assay:
0.17 ng/mL and 0.35 ng/mL of insulin, respectively (S3 Fig, Panel A). Though the ELISA assay
had slightly lower LOD and LOQ values (0.05 and 0.13 ng/mL insulin, respectively; S3 Fig,
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Fig 3. HTRFmeasurement of insulin secretion in INS-1E cells. (A)Glucose stimulation (20 mM, 37°C) significantly increased insulin secretion from
pancreatic beta cell-derived INS-1E cells after 30, 60 and 90 min of treatment compared to unstimulated control (0 mM glucose; p<0.001). (B) Levels of
secreted insulin in response to glucose stimulation (20 mM glucose, 90 min, 37°C) increased as a function of seeding cell density (R2 = 0.99); range of
variability is indicated by the dotted lines representing SEM above and below the respective points. (C) Cells were stimulated with increasing concentrations
of glucose (0.3–30 mM; 90 min, 37°C) and the resulting insulin secretion was fit to a sigmoidal curve (EC50 = 5.91 ± 0.02 mM, R
2 = 0.85). Data are
represented as %maximal insulin secretion based on mean HTRF values ± SEM from n3 independent experiments. HTRFmeasurements were performed
in 96-well plates with secretion experiments performed in triplicate.
doi:10.1371/journal.pone.0148684.g003
Fig 4. Comparison between HTRF and ELISA insulin detection assays. Supernatants collected from
glucose-stimulated INS-1E cells (20 mM glucose, 90 min, 37°C) were measured concurrently with HTRF or
ELISA insulin assays. The respective HTRF and ELISA assay-derived insulin concentration values were
plotted. A linear regression curve of the data showed close correlation of the insulin values from the two
methods (slope = 1.15 ± 0.16, R2 = 0.84). Results are represented as mean insulin concentrations ± SEM
performed in triplicate in 3 independent experiments.
doi:10.1371/journal.pone.0148684.g004
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Panel B), the HTRF assay had a superior signal to noise ratio (SNR) of 10.02 compared to 6.68
for ELISA–a ~50% improvement. Further, we calculated the Z´-factor for the HTRF assay to
be 0.89 (1 versus 10 ng/mL insulin; S4 Fig, Panel A), demonstrating that the assay is suitable
for high-throughput screening (HTS) (where the Z´-factor is typically0.50) [35]. We also
determined the Z´-factor for the cell-based secretion assay to be 0.64 (S4 Fig, Panel B), which
takes into account variability of secretion intrinsic to GSIS [15] and is similar to the Z´-factor
calculated for other fluorescence-based insulin secretory assays intended for HTS, including
the recently developed luciferase-tagged insulin reporter (Z´-factor = 0.62) [9,45].
To complement the findings in INS-1E cells, we used the HTRF insulin assay to measure
GSIS directly in isolated wildtype C57Bl6/J mouse-derived pancreatic islets. Similar to our find-
ings in INS-1E cells, there was a 4-fold increase in insulin release in response to stimulation
with 20 mM glucose compared to the unstimulated control (2.8 mM glucose, 90 min, 37°C; Fig
5A). We were able to detect GSIS from single islets (p<0.001; Fig 5B), underscoring the appli-
cability of our assay to future higher-throughput applications. In addition to secreted insulin,
we also measured intra-islet insulin concentrations in wildtype pancreatic islets. We found that
the intra-islet insulin concentration per islet was 187.2 ng/mL, which is consistent with previ-
ously reported values [46]. Moreover, the intracellular insulin concentration per islet remained
relatively constant, whereas the insulin concentration per well increased in proportion to the
islet number (5 islets/well: 902.4 ± 47.3 ng/mL; 10 islets/well: 1938.7 ± 47.3 ng/mL) (S5 Fig)
Given recent work suggesting that DA can decrease GSIS as part of an autocrine and/or
paracrine negative feedback mechanism [3,16,17], we applied the HTRF insulin assay to our
cell-based system both to further elucidate the role of DA in GSIS as well as to provide addi-
tional validation of the assay in a biological context. We found that DA dose-dependently
inhibited GSIS in INS-1E cells (IC50 = 1.28 ± 0.06 μM, R
2 = 0.93; Fig 6A). Maximal inhibition
was achieved at 10 μMDA, which fully blocked GSIS (defined as the difference between maxi-
mal stimulated and basal insulin secretion). Similarly, DA treatment (10 μM) of islets signifi-
cantly inhibited GSIS by 70.7 ± 6.8% (p<0.001; Fig 6B). These data provided the requisite
proof-of-principle confirmation of our assay’s ability to detect effects of dopaminergic signal-
ing on GSIS.
Beyond validation of the HTRF assay, we used the assay to shed light on the cellular mecha-
nisms of action of bromocriptine, which has recently been approved for improving glycemic
control in type II diabetes [20,22]. Though bromocriptine lowers elevated blood glucose and
insulin levels in rodent models [47–50] as well as in humans [21,51–54], the precise mecha-
nisms by which this drug achieves these effects remain poorly understood. To date, the major-
ity of work studying bromocriptine’s metabolic effects has focused on its actions in the central
nervous system (CNS) [18]. However, a potentially important clue to elucidating the drug’s
metabolic actions is its agonism of D2R and D3R [55]. Thus, given our data here, prior work
demonstrating a role for DA signaling in inhibiting pancreatic islet GSIS [3,16,17], and evi-
dence of D2R and D3R expression in insulin-secreting pancreatic islets [16], we hypothesized
that bromocriptine may act directly on pancreatic islet D2R and/or D3R to modify GSIS. Con-
sistent with this hypothesis, 10 μM bromocriptine significantly reduced GSIS by 67.4 ± 8.1% in
mouse islets (p<0.001) which is a level of GSIS inhibition similar to that caused by DA (Fig
6B). These findings validate earlier reported findings [24] and suggest that, in addition to its
actions in the CNS, bromocriptine can also act directly on pancreatic islets.
While we and colleagues demonstrated earlier that DA D2-like receptors are expressed in
insulin-secreting pancreatic beta cells [3,16,17], there is recent evidence in both rat and human
islets suggesting that other pancreatic islet cell types (alpha, delta and pancreatic polypeptide
cells) also express DA receptors (including D2R) [56,57]. This opens the possibility that bro-
mocriptine’s inhibition of GSIS may be due to the drug’s effects on multiple dopamine
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Fig 5. HTRFmeasurement of GSIS in pancreatic islets. (A) The HTRF insulin assay was applied to wildtype C57Bl6/J mouse-derived pancreatic islets.
Islets (10/well) stimulated with 20 mM glucose demonstrated 3.8-fold stimulation of insulin secretion compared to the unstimulated control (2.8 mM glucose;
p<0.001). (B) The HTRF insulin assay detected robust GSIS in single mouse islets, compared to unstimulated individual islets (p<0.001). Data are
represented as %maximal insulin secretion (Panel A) or as secreted insulin concentration (ng/mL; Panel B) based on mean HTRF values ± SEM from n3
independent experiments. HTRFmeasurements were performed in hextuplicate in 96-well plates.
doi:10.1371/journal.pone.0148684.g005
Fig 6. HTRFmeasurement of dopamine and bromocriptine effects on insulin secretion in cells and islets. (A) Increasing concentrations of dopamine
(DA) caused dose-dependent inhibition of GSIS in INS-1E cells, which was best fit to a sigmoidal curve (IC50 = 1.28 ± 0.06 μM, R
2 = 0.93). (B) Similarly,
treatment of wildtype mouse islets with 10 μMDA significantly and comparably inhibited GSIS (p<0.001) by 70.7 ± 6.8%. Consistent with a role for
dopaminergic signaling as a negative mediator of GSIS, treatment of islets with10 μM bromocriptine inhibited GSIS by 67.4 ± 8.1%. For INS-1E cell-based
and mouse islet experiments (Panels A and B, respectively), data are represented as %maximal insulin secretion based on mean HTRF values ± SEM from
n3 independent experiments. For all panels, HTRFmeasurements were performed in 96-well plates with INS-1E cell secretion experiments performed in
triplicate and mouse islet experiments performed in hextuplicate.
doi:10.1371/journal.pone.0148684.g006
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receptor-expressing islet cell types. Taken together, these data provide a framework with which
to further dissect the underlying molecular mechanisms for bromocriptine’s clinically-relevant
effects on insulin release [18,20,21].
Conclusions
We have demonstrated that our HTRF-based insulin assay is a powerful tool with several
advantages over the current predominantly used approaches for insulin measurement (i.e.
ELISA and RIA) including the ability to rapidly and effectively measure insulin secretion with
fewer steps and at less cost per sample (summarized in Table 1 and S1 Table). The HTRF insu-
lin assay provides a platform not only for the identification of novel mechanisms regulating
GSIS but also for further development of rapid HTS assays with which to identify new therapies
for disorders of insulin secretion, thus significantly expanding our methodological toolbox.
Supporting Information
S1 Fig. Insulin antibody recognition of mature versus immature forms of insulin. Insulin
antibodies exhibited significantly greater recognition of mature human insulin (in blue) com-
pared to human proinsulin across a range of concentrations (0–200 pM) [(F1, 5) = 14.00;
p = 0.01). At concentrations up to 100 pM, there was10% recognition of proinsulin com-
pared to mature insulin. There was no recognition of human C-peptide (in green) by the insu-
lin antibodies even at concentrations as high as 20 μM. Data are represented as %ΔF of the
HTRF signal for the respective insulin species and are from experiments performed in triplicate
in 384-well plates.
(TIF)
S2 Fig. Secreted insulin relative to total cellular stores. The percentage of insulin secreted
from INS-1E cells relative to total cellular stores increased 4-fold in response to glucose stimu-
lation (20 mM, 90 min, 25°C) compared to the unstimulated (0 mM glucose) control
(p<0.001). Results are represented as mean percentages ± SEM from 3 independent experi-
ments performed in triplicate.
(TIF)
S3 Fig. Limits of Detection and Quantitation for HTRF and ELISA insulin assays. (A) The
limit of detection (LOD) for the HTRF insulin assay (0.165 ng/mL insulin) was derived from
Table 1. Advantages of the HTRF-based insulin assay compared to ELISA and RIA approaches. Here we show the main advantages of an HTRF insu-
lin assay over comparable RIA and ELISA-based methods. Though all three methods are similarly sensitive and specific for insulin detection, the homoge-
nous nature of the HTRF assay eliminates numerous reagents and mixing, washing and blocking steps, making the assay shorter, less expensive and more
amenable to medium and high-throughput screens.
HTRF ELISA RIA
Fewer steps: Prepare fewer solutions and
mix fewer reagents
Many time-intensive steps: Multiple incubation,
blocking and washing steps
Many time-intensive steps: Long incubation steps
and high number of reagents
Lowest cost per sample ($0.02/sample) Relatively High cost per sample (>$2/sample) Medium to high cost per sample ($~1.50/sample)
Results within 2 h Results from 4 h to overnight Multiple-day results
Non-radioactive Non-radioactive Radiation exposure risk
Amenable to medium/high throughput
screening
Relatively low throughput Relatively low throughput
Homogenous assay Non-homogenous assay Non-homogenous assay
Highly sensitive and specific Highly sensitive and specific Highly sensitive and specific
doi:10.1371/journal.pone.0148684.t001
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the sum of the mean HTRF ratiometric signals from 48 separate blank samples (0 ng/mL insu-
lin) + 3 standard deviations from the mean. Likewise, limit of quantitation (LOQ) for the
HTRF ratio (0.345 ng/mL insulin) was calculated from the mean HTRF ratio from the blank
samples as above + 10 standard deviations from this mean. These values were then fit to a low
concentration range insulin standard curve (0.156–1.250 ng/mL) to obtain the insulin concen-
trations corresponding to the HTRF assay LOD (in black) or LOQ (in red). (B)We calculated
the LOD and LOQ for the ELISA insulin assay (0.05 and 0.13 ng/mL insulin, respectively) simi-
larly by fitting the corresponding ECL signal to the low concentration range insulin standard
curve (0.100–1.000 ng/mL),
(TIFF)
S4 Fig. Z´-factor measurements for the HTRF insulin assay. (A) The Z´-factor for the HTRF
assay was measured comparing 1 ng/mL versus 10 ng/mL insulin, which yielded a Z´-factor
score of 0.89. Similarly, a comparison of 2.5 ng/mL versus 10 ng/mL provided a Z´-factor score
of 0.85. Results were based on calculations from 40 data points of insulin concentrations and
were originally presented as a poster [58]. (B) The HTRF values measured from supernatants
of glucose-stimulated (20 mM glucose, 90 min, 37°C) and unstimulated (0 mM glucose, 90
min, 37°C) INS-1E cells were also used to calculate the Z´-factor (described in the Materials
and Methods); n = 24 replicate samples for both stimulated and unstimulated conditions. Bro-
ken lines indicate 3 standard deviations from the mean of each respective group. The Z´-factor
score of 0.64 indicates the assay’s suitability for high-throughput studies.
(TIFF)
S5 Fig. HTRF measurement of intra-islet insulin. The HTRF insulin assay was used to deter-
mine the intra-islet insulin concentration using pancreatic islets from wildtype C57Bl6/J mice.
Intra-islet insulin was measured from islet lysates collected from either 5 or 10 islets per well;
the insulin concentration per well increased in proportion to the islet number (5 islets/well:
902.4 ± 47.3 ng/mL; 10 islets/well: 1938.7 ± 47.3 ng/mL). Data are represented as total intra-
islet insulin concentration (ng/mL) based on mean HTRF values ± SEM; HTRF measurements
were performed in hextuplicate in 96-well plates.
(TIFF)
S1 File. NC3Rs ARRIVE Guidelines Checklist.We abided by all appropriate animal care
guidelines as outlined in the ARRIVE guidelines checklist for reporting animal research.
(PDF)
S1 Table. Step by step comparison of HTRF versus ELISA and RIA-based approaches to
insulin detection. Comparison of HTRF, ELISA and RIA-based insulin detection approaches
emphasizes the significantly reduced number of steps associated with the HTRF assay versus
the predominantly used ELISA and RIA methods: 4 steps for HTRF compared to 16 and 15
steps for ELISA and RIA methods, respectively.
(PDF)
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